Oncolytic adenovirus decreases the proportion of TIM-3 + subset of tumor-infiltrating CD8 + T cells with correlation to improved survival in patients with cancer.

Ilkka LiikanenSaru BasnetDafne C A QuixabeiraKristian TaipaleOtto HemminkiMinna OksanenMatti KankainenJuuso JuhilaAnna KanervaTimo JoensuuSiri TähtinenAkseli E Hemminki

Published in: Journal for immunotherapy of cancer (2022)

Our results indicate a key role for the TIM-3 immune checkpoint in oncolytic adenoviral immunotherapy. Moreover, our results identify TIM-3 as a potential biomarker for oncolytic adenoviruses and create rationale for combination with passive immunotherapy for a subset of patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
clinical trial
patient reported outcomes
nk cells